QSB 490
Alternative Names: QSB-490Latest Information Update: 23 Jul 2021
At a glance
- Originator Q-State Biosciences
- Class Antisense oligonucleotides; Antispastics; Neuroprotectants
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Spastic paralysis
Most Recent Events
- 28 Jun 2021 Preclinical trials in Spastic paralysis in USA (unspecified route), prior to June 2021
- 28 Jun 2021 Pharmacodynamics data from preclinical trials in Spastic paralysis released by Q-State Biosciences
- 28 Jun 2021 Q-State Biosciences and the Luke Heller TECPR2 Foundation anticipate initiation of a clinical trial in Spastic paralysis, in the second half of 2021